CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

June 27, 2018

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2024

Conditions
Non Small Cell Lung CancerTriple Negative Breast CancerMelanomaHead and Neck Cancer
Interventions
BIOLOGICAL

CAB-ROR2-ADC

Conditionally active biologic anti-ROR2 antibody drug conjugate

BIOLOGICAL

PD-1 inhibitor

PD-1 inhibitor

Trial Locations (59)

10016

NYU Langone Health, New York

10032

Columbia University Medical Center, New York

11526

HENRY DUNANT Hospital Center, 4th Department of Medical Oncology and Clinical Trials Unit, Athens

14263

Roswell Park, Buffalo

15232

UPMC Cancer Center, Pittsburgh

18547

"Metropolitan Hospital Perseus Healthcare Group SA 4th Oncology Department", Piraeus

27157

Wake Forest Baptist Health, Winston-Salem

28027

University Clinic of Navarra - Madrid, Madrid

28041

University Hospital 12 de Octubre, Madrid

28374

FirstHealth Outpatient Cancer Center, Pinehurst

29407

Medical University of South Carolina- Hollings Cancer Center, Charleston

30912

Augusta University - Georgia Cancer Center, Augusta

32003

Florida Cancer Specialists & Research Institute, Fleming Island

33028

Memorial Cancer Institute (MCI), Hollywood

33401

Florida Cancer Specialists, West Palm Beach

33612

Memorial Sloan-Kettering Cancer Center, Tampa

Moffitt Cancer Center, Tampa

33916

Florida Cancer Specialists & Research Institute, Fort Myers

34474

Florida Cancer Specialist - North, St. Petersburg

37203

Sarah Cannon Research Institute, Nashville

40241

Norton Cancer Institute, Brownsboro Hospital Campus, Louisville

40503

Baptist Health Systems, Lexington

40536

University of Kentucky, Lexington

41014

University Hospital Nuestra Senora de Valme, Seville

45219

The Christ Hospital, Cincinnati

54622

Bioclinic Thessaloniki, Οncology Department, Thessaloniki

57001

European Interbalkan Medical Center, Οncology Department, Thessaloniki

70809

Hematology/Oncology Clinic, Baton Rouge

75230

Mary Crowley Cancer Research, Dallas

77030

MD Anderson Cancer Center, Houston

80045

University of Colorado, Aurora

80218

Sarah Cannon Research Institute at Health One, Denver

84112

University of Utah - Huntsman Cancer Institute, Salt Lake City

85724

University of Arizona Cancer Center, Tucson

89169

Comprehensive Cancer Care of Nevada, Las Vegas

OptumCare Cancer Care, Las Vegas

90027

California Research Institute, Los Angeles

90033

USC Norris, Los Angeles

90603

American Institute of Research, Whittier

91010

City of Hope - Duarte, Duarte

92093

University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla

92868

UC Irvine Medical Center - Chao Family Comprehensive Cancer Center, Orange

94158

University of California San Francisco, San Francisco

97239

Oregon Health & Science University, Portland

02215

Dana-Farber Cancer Institute, Boston

Unknown

Prince of Wales Hospital, Hong Kong

Queen Mary Hospital, Hong Kong

Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City

National Cheng Kung University Hospital, Tainan City

National Taiwan University Hospital, Taipei

LinKou Chang Gung Memorial Hospital, Taoyuan

60-693

MED-Polonia, Sp. z o.o. (LLC), Poznan

20-609

Institute of Genetics and Immunology GENIM LCC in Lublin, Lublin

08-781

Malgorzata Kozlik, Warsaw

93-338

Polish Mother's Memorial Hospital-Research Institute, Lodz

97-200

Beata Głogowska, Tomaszów Mazowiecki

08041

Hospital de la Santa Creu i Sant Pau, Barcelona

089003

Hospital del Mar, Barcelona

08908

Anna Ramos Luna, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

BioAtla, Inc.

INDUSTRY